Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Childress

Showing results (41-50 of 86) with videos related to

Pageof 9
Sort By:
Clinical Therapeutics|November 10, 2020
A Post Hoc Comparison of Prior ADHD Medication Dose and Optimized Delayed-release and Extended-release Methylphenidate Dose in a Pivotal Phase III TrialAnn C Childress, Cassandra L Uchida, Michelle D Po, et al.
Journal of Child and Adolescent Psychopharmacology|June 3, 2021
Open-Label Dose Optimization of Methylphenidate Extended-Release Orally Disintegrating Tablet in a Laboratory Classroom Study of Children with Attention-Deficit/Hyperactivity DisorderAnn C Childress, Scott H Kollins, Andrew J Cutler, et al.
Journal of Child and Adolescent Psychopharmacology|May 17, 2016
Efficacy, Safety, and Tolerability of an Extended-Release Orally Disintegrating Methylphenidate Tablet in Children 6-12 Years of Age with Attention-Deficit/Hyperactivity Disorder in the Laboratory Classroom SettingAnn C Childress, Scott H Kollins, Andrew J Cutler, et al.
CNS Drugs|October 6, 2017
Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents With Attention-Deficit/Hyperactivity DisorderJeffrey H Newcorn, Peter Nagy, Ann C Childress, et al.
Journal of Child and Adolescent Psychopharmacology|December 22, 2018
Early-Onset Efficacy and Safety Pilot Study of Amphetamine Extended-Release Oral Suspension in the Treatment of Children with Attention-Deficit/Hyperactivity DisorderAnn C Childress, Judith C Kando, Thomas R King, et al.
Melanoma Research|February 6, 2003
Concurrent interferon-alpha and radiation for head and neck melanomaN P Nguyen, B Levinson, S Dutta, et al.
Expert Review of Neurotherapeutics|March 11, 2026
Centanafadine to treat ADHD in children and adolescents: a plain language summary of publicationCaroline L Ward, Na Jin, Osman Turkoglu, et al.
Journal of the American Academy of Child and Adolescent Psychiatry|May 16, 2022
Efficacy and Safety of Lisdexamfetamine in Preschool Children With Attention-Deficit/Hyperactivity DisorderAnn C Childress, Eric Lloyd, Leslie Jacobsen, et al.
Journal of Child and Adolescent Psychopharmacology|August 18, 2017
SHP465 Mixed Amphetamine Salts in the Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents: Results of a Randomized, Double-Blind Placebo-Controlled StudyMatthew Brams, Ann C Childress, Michael Greenbaum, et al.
Journal of the American Academy of Child and Adolescent Psychiatry|July 6, 2025
Centanafadine for Attention-Deficit/Hyperactivity Disorder in Adolescents: A Randomized Clinical TrialCaroline L Ward, Ann C Childress, Na Jin, et al.
Pageof 9

Showing results (41-50 of 86) with videos related to

Sort By:
Pageof 9
Clinical Therapeutics|November 10, 2020
A Post Hoc Comparison of Prior ADHD Medication Dose and Optimized Delayed-release and Extended-release Methylphenidate Dose in a Pivotal Phase III TrialAnn C Childress, Cassandra L Uchida, Michelle D Po, et al.
Journal of Child and Adolescent Psychopharmacology|June 3, 2021
Open-Label Dose Optimization of Methylphenidate Extended-Release Orally Disintegrating Tablet in a Laboratory Classroom Study of Children with Attention-Deficit/Hyperactivity DisorderAnn C Childress, Scott H Kollins, Andrew J Cutler, et al.
Journal of Child and Adolescent Psychopharmacology|May 17, 2016
Efficacy, Safety, and Tolerability of an Extended-Release Orally Disintegrating Methylphenidate Tablet in Children 6-12 Years of Age with Attention-Deficit/Hyperactivity Disorder in the Laboratory Classroom SettingAnn C Childress, Scott H Kollins, Andrew J Cutler, et al.
CNS Drugs|October 6, 2017
Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents With Attention-Deficit/Hyperactivity DisorderJeffrey H Newcorn, Peter Nagy, Ann C Childress, et al.
Journal of Child and Adolescent Psychopharmacology|December 22, 2018
Early-Onset Efficacy and Safety Pilot Study of Amphetamine Extended-Release Oral Suspension in the Treatment of Children with Attention-Deficit/Hyperactivity DisorderAnn C Childress, Judith C Kando, Thomas R King, et al.
Melanoma Research|February 6, 2003
Concurrent interferon-alpha and radiation for head and neck melanomaN P Nguyen, B Levinson, S Dutta, et al.
Expert Review of Neurotherapeutics|March 11, 2026
Centanafadine to treat ADHD in children and adolescents: a plain language summary of publicationCaroline L Ward, Na Jin, Osman Turkoglu, et al.
Journal of the American Academy of Child and Adolescent Psychiatry|May 16, 2022
Efficacy and Safety of Lisdexamfetamine in Preschool Children With Attention-Deficit/Hyperactivity DisorderAnn C Childress, Eric Lloyd, Leslie Jacobsen, et al.
Journal of Child and Adolescent Psychopharmacology|August 18, 2017
SHP465 Mixed Amphetamine Salts in the Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents: Results of a Randomized, Double-Blind Placebo-Controlled StudyMatthew Brams, Ann C Childress, Michael Greenbaum, et al.
Journal of the American Academy of Child and Adolescent Psychiatry|July 6, 2025
Centanafadine for Attention-Deficit/Hyperactivity Disorder in Adolescents: A Randomized Clinical TrialCaroline L Ward, Ann C Childress, Na Jin, et al.
Pageof 9